HYPERHEP B

This brand name is authorized in United States. It is also authorized in Canada, Hong Kong SAR China, Israel, New Zealand, Singapore, Turkey.

Active ingredients

The drug HYPERHEP B contains one active pharmaceutical ingredient (API):

1	Human hepatitis B immunoglobulin UNII XII270YC6M - HUMAN HEPATITIS B VIRUS IMMUNE GLOBULIN
	Human hepatitis B immunoglobulin solution for infusion contains mainly immunoglobulin G (IgG) with a specifically high content of antibodies against hepatitis B virus surface antigen (HBs). It is used for the immunoprophylaxis of hepatitis B and the prevention of hepatitis B virus re-infection after liver transplantation for hepatitis B induced liver failure.
	Read more about Human hepatitis B immunoglobulin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
HYPERHEP B Solution for injection	MPI, US: SPL/Old	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J06BB04	Hepatitis B immunoglobulin	J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins → J06BB Specific immunoglobulins
Discover more medicines within J06BB04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02230738, 02379465
HK	Department of Health Drug Office	54263
IL	מִשְׂרַד הַבְּרִיאוּת	8931, 8932
NZ	Medicines and Medical Devices Safety Authority	7718
SG	Health Sciences Authority	09669P, 13490P, 13491P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699769980160, 8699769980177, 8699769980184
US	FDA, National Drug Code	13533-636